Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

DiaMedica Therapeutics Inc. DMAC NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
52/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$8.33
+27.4%

DiaMedica Therapeutics Inc. (DMAC) is a Biotechnology company in the Healthcare sector, currently trading at $6.54. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is DMAC = $8 (+27.4% upside).

Valuation: DMAC trades at a trailing Price-to-Earnings (P/E) of -8.8 (S&P 500 average ~25).

Net income is $33M (loss), growing at -34%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $240,000 against $56M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 11.81 (strong liquidity). Debt-to-assets is 0.4%. Total assets: $61M.

Analyst outlook: 6 / 6 analysts rate DMAC as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 94/100 (Pass), Income ?/100 (Fail).

$8.33
▲ 27.37% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for DiaMedica Therapeutics Inc., the average price target is $8.33, with a high forecast of $10.00, and a low forecast of $7.00.
Highest Price Target
$10.00
Average Price Target
$8.33
Lowest Price Target
$7.00

DMAC SharesGrow Score Overview

62/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 75/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — DMAC

✓
VALUE Pass
75/100
DMAC trades at a trailing Price-to-Earnings (P/E) of -8.8 (S&P 500 average ~25). Forward PEG -0.9 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $8, implying +22.3% from the current price $7. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
DMAC: +0%/yr revenue is, -34%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet DMAC: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 11.81 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
DMAC: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 6 / 6 analysts rate DMAC as buy (100%). Analyst consensus target is $8 (+22.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range3.19-10.4195
Volume142.16K
Avg Volume (30D)245.57K
Market Cap$352.39M
Beta (1Y)1.15
Share Statistics
EPS (TTM)-0.70
Shares Outstanding$46.98M
IPO Date2012-08-03
Employees27
CEODietrich John Pauls
Financial Highlights & Ratios
EBITDA$-34.35M
Net Income$-32.77M
Operating Income$-34.4M
Total Cash$59.89M
Total Debt$240K
Net Debt$-15.41M
Total Assets$61.37M
Price / Earnings (P/E)-9.3
Analyst Forecast
1Y Price Target$8.00
Target High$10.00
Target Low$7.00
Upside+22.3%
Rating ConsensusBuy
Analysts Covering6
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINCA25253X2077

Price Chart

Track all markets on TradingView
DMAC
DiaMedica Therapeutics Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
3.19 52WK RANGE 10.42

People Also View

CNTA
CNTA
Centessa Pharmaceuticals plc
$39.59
+0.05%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 IOVA
IOVA
Iovance Biotherapeutics, Inc.
$3.64
+5.20%
 LIFE
LIFE
aTyr Pharma, Inc.
$14.69
+2.23%
 SCPH
SCPH
scPharmaceuticals Inc.
$5.67
+0.00%
 MIST
MIST
Milestone Pharmaceuticals Inc.
$2.03
+1.50%
 IKT
IKT
Inhibikase Therapeutics, Inc.
$1.70
-0.58%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message